The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.
J. Shamash
Research Funding - Chugai Pharma
J. Jacob
No relevant relationships to disclose
T. Powles
No relevant relationships to disclose
S. Agrawal
Research Funding - Chugai Pharma
K. Mutsvangwa
No relevant relationships to disclose
N. Saunders
No relevant relationships to disclose
P. Wilson
No relevant relationships to disclose
J. Stebbing
No relevant relationships to disclose